{"nctId":"NCT01309646","briefTitle":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","startDateStruct":{"date":"2011-03-04","type":"ACTUAL"},"conditions":["Poliomyelitis","Tetanus","Acellular Pertussis","Diphtheria","Haemophilus Influenzae Type b"],"count":454,"armGroups":[{"label":"Infanrix-IPV+Hib Group","type":"EXPERIMENTAL","interventionNames":["Biological: Infanrix™-IPV+Hib","Biological: Synflorix™","Biological: Rotarix™"]},{"label":"Infanrix IPV Group","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Infanrix™ IPV","Biological: Hiberix™","Biological: Synflorix™","Biological: Rotarix™"]}],"interventions":[{"name":"Infanrix™-IPV+Hib","otherNames":[]},{"name":"Infanrix™ IPV","otherNames":[]},{"name":"Hiberix™","otherNames":[]},{"name":"Synflorix™","otherNames":[]},{"name":"Rotarix™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A male or female between, and including, 42 and 69 days of age at the time of the first vaccination.\n* Born after a gestation period of 37 to 42 weeks inclusive.\n* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.\n* Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Child in care.\n* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose, or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.\n* Administration of a vaccine not foreseen by the study protocol, within 30 days prior to the first study visit, with the exception of hepatitis B and Bacillus Calmette-Guérin vaccination; or planned administration during the study period, with the exception of hepatitis B and influenza vaccines, which will be allowed at least 7 days before or 30 days after the administration of the DTPa vaccine.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.\n* Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis and Hib vaccination or disease.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Family history of congenital or hereditary immunodeficiency.\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).\n* Major congenital defects or serious chronic illness.\n* History of any neurological disorders or seizures.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.\n* Acute disease and/or fever at the time of enrolment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"69 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.","description":"A seroprotected subject was defined as a vaccinated subject who had an anti-D and anti-T antibody concentration equal to or above (≥) 0.1 international units per milliliter (IU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects for Anti-poliovirus (Anti-polio) Types 1, 2 and 3.","description":"A seroprotected subject was defined as a vaccinated subject who had an anti-polio types 1, 2 and 3 antibody titres equal to or above (≥) 8, cut off corresponding to the effective dose for 50% of the vaccinated subjects.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.","description":"A seroprotected subject was defined as a vaccinated subject who had an anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations.","description":"Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of 5 ELISA units per milliliter (EL.U/mL).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"134.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.8","spread":null},{"groupId":"OG001","value":"133.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects for Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN).","description":"A seropositive subjects was defined as a vaccinated subjects who had an anti-PRN, anti-PT and anti-FHA antibody concentration ≥ 5 ELISA units per milliliter (EL.U/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"178","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-pertussis Toxoid (PT), Anti-filamentous Haemagglutinin (FHA) and Anti-pertactin (PRN) Antibody Concentrations","description":"Concentrations were expressed as geometric mean concentrations (GMCs) for the seropositivity cut-off of 5 EL.U/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null},{"groupId":"OG001","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies.","description":"A seroprotected subject was defined as a vaccinated subject who had an anti-D and anti-T antibody concentration equal to or above (≥) 0.1 international units per milliliter (IU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations for Anti-D and Anti-T Antibodies.","description":"Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.058","spread":null},{"groupId":"OG001","value":"0.060","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.096","spread":null},{"groupId":"OG001","value":"8.692","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.081","spread":null},{"groupId":"OG001","value":"0.091","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.259","spread":null},{"groupId":"OG001","value":"12.421","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects Anti-poliovirus (Anti-polio) Types 1, 2 and 3.","description":"A seroprotected subject was defined as a vaccinated subject who had an anti-polio types 1, 2 and 3 antibody titres equal to or above (≥) 8, cut off corresponding to the effective dose for 50% of the vaccinated subjects.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Titres for Anti-polio Types 1, 2 and 3.","description":"Titres were expressed as geometric mean titres (GMTs). The seroprotection cut-off of the assay was 8.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"328.8","spread":null},{"groupId":"OG001","value":"372.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"340.6","spread":null},{"groupId":"OG001","value":"400.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"377.7","spread":null},{"groupId":"OG001","value":"465.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected Subjects for Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibodies.","description":"A seroprotected subject was defined as a vaccinated subject who had an anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Concentrations of Anti-PRP Antibodies.","description":"Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.15 µg/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.165","spread":null},{"groupId":"OG001","value":"0.219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.456","spread":null},{"groupId":"OG001","value":"18.700","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With a Vaccine Response to Anti-PT, Anti-FHA and Anti-PRN.","description":"Vaccine response was defined as antibody concentration ≥ 5 EL.U/mL at post vaccination, for initially seronegative subjects, and at least maintenance of antibody concentration from pre to post-vaccination (i.e. antibody concentration at post vaccination ≥ 1 fold the pre-vaccination antibody concentration), for initially seropositive subjects.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"215","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited Local Symptoms.","description":"Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"146","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"167","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Solicited General Symptoms.","description":"Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and fever \\[defined as tympanic temperature ≥ 37.5 degrees Celsius (°C)\\]. Any = incidence of a particular symptom regardless of intensity grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"182","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs).","description":"Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Serious Adverse Events (SAEs).","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":224},"commonTop":["Irritability/Fussiness","Redness","Drowsiness","Pain","Swelling"]}}}